Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Molecular Templates revenue
Molecular Templates's revenue is $38.7 million.
What is Molecular Templates's revenue?
- Molecular Templates's revenue growth from 2011 to 2021 is 62,314.52%.
- Molecular Templates has 261 employees, and the revenue per employee ratio is $148,264.
- Molecular Templates's peak quarterly revenue was $11.1M in 2024(q1).
- Molecular Templates peak revenue was $76.9M in 2015.
- Molecular Templates annual revenue for 2020 was 18.8M, -15.38% growth from 2019.
- Molecular Templates annual revenue for 2021 was 38.7M, 105.34% growth from 2020.
On this page
Zippi applies for you, and finds you a job.
Molecular Templates historical revenue
Molecular Templates's peak revenue was $76.9M in 2015. The peak quarterly revenue was $11.1M in 2024(q1).
Molecular Templates's revenue increased from $62.0k in 2011 to $38.7M currently. That's a 62,314.52% change in annual revenue.
Molecular Templates annual revenue
Molecular Templates annual revenue over time
| Fiscal year / year | Molecular Templates revenue |
|---|---|
| 2011 | $62,000 |
| 2012 | $5.9M |
| 2013 | $12.5M |
| 2014 | $14.7M |
| 2015 | $76.9M |
| 2016 | $1.9M |
| 2017 | $3.4M |
| 2018 | $13.3M |
| 2019 | $22.3M |
| 2020 | $18.8M |
| 2021 | $38.7M |
How accurately did Molecular Templates' revenue projections match actual performance?
Molecular Templates annual growth
Molecular Templates saw the greatest revenue growth in 2012, when revenue increased by 9,362.9%.
Molecular Templates had the lowest revenue growth in 2016, when revenue changed by -97.56%.
Molecular Templates annual growth rate over time
| Year | Molecular Templates growth |
|---|---|
| 2012 | 9363%↑ |
| 2013 | 113%↑ |
| 2014 | 18%↑ |
| 2015 | 422%↑ |
| 2016 | -98%↓ |
| 2017 | 81%↑ |
| 2018 | 291%↑ |
| 2019 | 68%↑ |
| 2020 | -15%↓ |
| 2021 | 105%↑ |
Molecular Templates jobs nearby
Do you work at Molecular Templates?
Is Molecular Templates transparent about its revenue structure?
Molecular Templates financial information
| CEO | Eric E. Poma |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 261 |
| Date Founded | 2000 |
| Headquarters | Austin, Texas |
| Number of Locations | 3 |
| Revenue | $38.7M |
| Net Income | -$92,718,000 |
| PE Ratio | -1.58 |
| Tax Rate | -0.0% |
| Market Capitalization | $131.4M |
| Total Assets | $97,548,000 |
| Ticker | MTEM |
Molecular Templates jobs you might like
Molecular Templates financing
Molecular Templates received early financing of $2.5M on 2009-05-03.
| Series | Round size | Date |
|---|---|---|
| Series A | $2.5M | 05/2009 |
| Grant | $154K | 01/2010 |
| Series B | $3.5M | 04/2011 |
| Series C | $8.5M | 10/2013 |
| Grant | $10.6M | 10/2013 |
| Series Unknown | $7M | 07/2014 |
| Series C | $3.5M | 09/2014 |
| Series D | $4.5M | 12/2015 |
| Post Ipo Equity | $60M | 08/2017 |
| Post Ipo Debt | $10M | 03/2018 |
| Post Ipo Equity | $52M | 09/2018 |
| Post Ipo Equity | $15.0M | 12/2019 |
| Post Ipo Debt | $45M | 03/2020 |
| Post Ipo Equity | $75.9M | 02/2021 |
Molecular Templates investors
| Investors | Security type |
|---|---|
| Sante Ventures | Series A |
| National Institutes of Health (NIH) | Grant |
| Excel Venture Management | Series C |
| Sante Ventures | Series C |
| Cancer Prevention & Research Institute of Texas | Grant |
| Excel Venture Management | Series Unknown |
| Sante Ventures | Series Unknown |
| Aju IB Investment | Series C |
| Sante Ventures | Series C |
| Sante Ventures | Series D |
| Takeda Pharmaceutical | Post Ipo Equity |
| Perceptive Advisors | Post Ipo Equity |
| Longitude Capital | Post Ipo Equity |
| Biotechnology Value Fund | Post Ipo Equity |
| CAM Capital | Post Ipo Equity |
| Perceptive Advisors | Post Ipo Debt |
| K2 HealthVentures | Post Ipo Debt |
| Frazier Healthcare Partners | Post Ipo Debt |
Molecular Templates competitors
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| MabVax Therapeutics | - | $1.6M | 11 | - |
| Allos Therapeutics | - | $76.0M | 175 | - |
| Ziopharm oncology | - | $6.4M | 48 | - |
| TG Therapeutics | - | $329.0M | 286 | - |
| Oncternal Therapeutics | - | $785,000 | 13 | - |
| Arvinas Inc. | - | $263.4M | 83 | - |
| Avalon Pharmaceuticals | - | $3.4M | 50 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Cell Signaling Technology | - | $48.0M | 500 | - |
| Lucigen | - | $15.7M | 20 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Molecular Templates highest paying jobs
Zippia gives an in-depth look into the details of Molecular Templates, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Molecular Templates. The employee data is based on information from people who have self-reported their past or current employments at Molecular Templates. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Molecular Templates. The data presented on this page does not represent the view of Molecular Templates and its employees or that of Zippia.
Molecular Templates may also be known as or be related to MOLECULAR TEMPLATES INC., Molecular Templates, Molecular Templates Inc and Molecular Templates, Inc.